Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06828991 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

A Phase 2 study of Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Danielle Wallace.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT06828991 is a Phase 2 study of Diffuse Large B Cell Lymphoma (DLBCL) that is actively recruiting participants, run by Danielle Wallace. The registered enrollment target is 40 participants, below the 259-participant average among 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06828991, a Phase 2 study of Diffuse Large B Cell Lymphoma (DLBCL), is actively recruiting participants, sponsored by Danielle Wallace.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity. Identifying which patients might benefit from more therapy at the end of first-line treatment is important. The ability to measure small amounts of persistent lymphoma (circulating tumor DNA or ctDNA) might allow the investigators to risk stratify patients. If older patients have detectable ctDNA in the blood at the end of six cycles of polatuzumab vedotin, rituximab and dose-attentuated CHP chemotherapy, patients will receive a bispecific antibody called mosunetuzumab. The investigators hypothesize this will result in "clearing" the ctDNA from the blood and result in better disease control and outcomes for patients. The study will also measure the safety of this regimen and the impact on the function of these older patients utilizing a tool called the geriatric assessment.

Conditions Studied

Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

  • DRUG Mosunetuzumab
  • DEVICE ClonoSEQ

Study Locations (1)

New York

  • Wilmot Cancer Institute - Rochester

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-09-04
Est. Completion 2030-04
Phase Phase 2

Sponsor

Danielle Wallace

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06828991

The ClinicalTrials.gov registry entry for NCT06828991 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 259-participant average among 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials with a reported enrollment target (85% lower). The listed sponsor is Danielle Wallace, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diffuse Large B Cell Lymphoma (DLBCL) appearing as the primary indexed condition, and to 2 interventions - of which Mosunetuzumab is the first listed.

NCT06828991 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06828991 about?

NCT06828991 is a clinical study titled "A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP". Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity. Identifying which patients might benefit from more therapy at the end of first-line treatment is important. The ability to measure small amounts ...

What is the current status of trial NCT06828991?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-09-04. Estimated completion is 2030-04.

What conditions does trial NCT06828991 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma (DLBCL).

What interventions are being tested in trial NCT06828991?

The interventions under investigation include: Mosunetuzumab (DRUG), ClonoSEQ (DEVICE).

Who is sponsoring clinical trial NCT06828991?

This trial is sponsored by Danielle Wallace, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06828991 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma (DLBCL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma (DLBCL)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.